How cost-effective are new preventive strategies for cardiovascular disease?
- 1 May 2003
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 91 (10), 22-27
- https://doi.org/10.1016/s0002-9149(03)00229-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Cost effectiveness of ramipril treatment for cardiovascular risk reductionHeart, 2001
- Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatmentHeart, 1999
- Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyThe Lancet, 1997
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Cost-effectiveness analysis in heart disease, part III: Ischemia, congestive heart failure, and arrhythmiasProgress in Cardiovascular Diseases, 1995
- Cost-effectiveness analysis in heart disease, part II: Preventive therapiesProgress in Cardiovascular Diseases, 1995
- Cost-effectiveness analysis in heart disease Part I: General principlesProgress in Cardiovascular Diseases, 1994
- Cost-effectiveness of HMG-CoA Reductase Inhibition for Primary and Secondary Prevention of Coronary Heart DiseasePublished by American Medical Association (AMA) ,1991
- Clinical EconomicsJAMA, 1989
- The Distinction Between Cost and ChargesAnnals of Internal Medicine, 1982